Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Actuate Therapeutics, Inc.

NASDAQ: ACTU · Life Sciences · 4 alerts · CIK 1652935

Share price
$0.2680Close, Nov 16
Market cap
$16.2M
Shares outstanding
60.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Actuate Therapeutics, Inc. filings on SEC EDGAR ↗

4:01 PM ET 10-Q
Financial Results

Actuate Therapeutics Q3 2026 Results: Net Loss of $3.42M, Loss Narrows

Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.

Key figure
Net loss $3.42M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.